Cobra Biologics has installed a state-of-the-art 1000L HyClone single-use bioreactor (SUB) from Thermo Fisher Scientific at its centre of excellence for mammalian antibody and recombinant protein production in Sodertalje, Sweden. The move is in response to customer demand and as a result of winning a new contract with a customer in North America.
Cobra says it has achieved a ten-fold increase in its antibody business over the last two years.
‘Antibody and other recombinant protein production has been a strong growth area for our specialised manufacturing site,’ said Peter Coleman, CEO of Cobra Biologics. ‘Cobra’s maxXpress cell line development and comprehensive analytics services are proving to be very attractive to customers. Demand is such that we have the confidence to invest for the future and we see this as just a stepping stone in the expansion of our capabilities at all three Cobra facilities.’
Cobra’s expansion began with the acquisition of a purpose built aseptic manufacturing facility in 2011, providing fill and finish services for pre-filled syringes, vials and freeze drying/lyophilisation for biologics and pharmaceuticals. The Thermo Scientific 1000L HyClone SUB, purchased through Finesse Solutions, marks a continuation of the company’s strategy for sustained growth.
Barbara Paldus, CEO at Finesse, said: ‘The addition of a 1000L vessel to the existing 50L and 250L Finesse control platform will present customers with a highly capable, scalable, and robust DeltaV-based cGMP bio-processing solution.’
